kinases such as the Aurora family of proteins; the Polo-like kinase; and the mitotic checkpoint proteins. 5, 7 Microtubules, the key components of the cytoskeleton, are composed of alpha and beta tubulin heterodimer. They are highly dynamic polymers that undergo polymerization and depolymerization in a short span of time and play essential role in the maintenance of cell shape, intracellular trafficking, cell motility and cell signalling apart from cell division and mitosis. 8 Tubulin has two nucleotide (GTP) binding sites and three well-characterized drug binding sites such as the colchicine binding site, the paclitaxel binding site and the Vinca alkaloid binding site. The GTP binding site is located at the N-terminal region of the α and the β subunits, and the colchicine binding site is present at the interface of the α-β subunit. 8, 9 The paclitaxel binding site is located at the β-tubulin, and the Vinca alkaloids binding site is located in the N-terminal region of the β-tubulin subunit close to the GTP binding site.
9
The clinically successful antitubulin agents such as the paclitaxel and the vinblastine are obtained from plants. Natural product research is gaining a huge attention because many of the phytochemicals exhibit excellent chemopreventive and chemotherapeutic potential in addition to their selectivity against cancer cells and low cost of production. 10 Natural products such as genistein, apigenin, quercetin, curcumin, berberine, limonene, coumarin, indirubin, brassinin, indole-3-carbinol, lycopene and resveratrol are in clinical/ preclinical trials either alone or in combination therapy for the treatment of cancer. [11] [12] [13] In the present study, we have investigated the anti-proliferative mechanism of the natural product zerumbone isolated from the plant Zingiber zerumbet belonging to the ginger family
of flowering plants (Zingiberaceae). Zerumbone is a sesquiterpene
and is reported to exhibit anti-cancer potential and other pharmacological activities such as anti-inflammatory, antibacterial, antimalarial and antioxidant properties. [14] [15] [16] [17] Zerumbone was found to be effective in preventing tumour angiogenesis by inhibiting the VEGF expression and NF-κB activity. 18 It was reported to induce apoptosis in various cancer cell lines by modulating the FAS and TRAIL signalling pathways, through enhanced expression of TNF and modulating Bax/Bcl-2 ratio . [19] [20] [21] Recently, zerumbone was reported to block the cell cycle at mitosis 17, 22 and induce apoptosis in cancer cells through inhibition of microtubule assembly. 23 However, the mechanism behind the mitotic block was not clearly established, and hence, we have performed this study to elaborate its anti-cancer mechanism through biophysical, biochemical and cell culture studies.
Cell culture studies showed an excellent observation that zerum- 
| MATERIAL S AND ME THODS

| Materials
Paclitaxel, vinblastine sulphate, podophyllotoxin, colchicine, 5,5′-dithiobis-2-nitrobenzoic acid (DTNB) HiMedia (Mumbai, India). Dichloromethane, n-hexane, hydroxylamine hydrochloride and triethylamine were purchased from Merck, India. 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride was purchased from SRL chemicals. All other reagents used in the study were of analytical grade.
| Isolation, purification and characterization of zerumbone
Fresh rhizomes of Zingiber zerumbet were collected from the farms of the Indian Institute of Spice Research (IISR), Calicut, Kerala (India), and it was authenticated by Dr D Prasath, Principal Scientist, IISR, Calicut. Zerumbone was extracted and isolated from the rhizomes of Zingiber zerumbet as described earlier. 24 Briefly, 1 kg of fresh rhizomes was washed under running tap water and cut into slices. The slices were then shade-dried at 37°C for 5 days. The dried samples were then soaked in methanol for 3 days, and the methanolic extract was concentrated by using the rotary evaporator (Heidolph and Bruker Avance III Nuclear Magnetic Resonance spectroscopy (NMR) using the standard procedure.
| Fluorescent labelling of zerumbone
Zerumbone does not have any characteristic fluorescence; hence, we labelled it with fluorescein isothiocyanate (FITC) by conjugating zerumbone oxime with fluoresceinthiocarbamyl ethylenediamine (EDF) to characterize the binding site of zerumbone on tubulin.
Zerumbone oxime was synthesized as described earlier. 25 In brief, zerumbone (0.3 g) was dissolved in 10 mL of ethanol containing 0.9 g of hydroxylamine hydrochloride and 1.8 g potassium carbonate. The mixture was stirred for 5 hours at room temperature. The reaction mixture was then filtered, and the residue was washed with methanol.
The filtrate was concentrated under reduced pressure and was then mixed with dichloromethane (10 mL). The organic layer was collected and washed with water. The resultant mixture was concentrated and dried to get crystalline zerumbone oxime, which was subjected to FTIR analysis. Fluoresceinthiocarbamyl ethylenediamine (EDF) was synthesized as described earlier. 26 Zerumbone oxime (20 mg), under an inverted Nikon ECLIPSE Ti (Tokyo, Japan) fluorescent microscope after adding AO (2 μg/mL), and the images were captured using the CoolSNAP digital camera.
| Cell migration assay
HeLa cells (1 × 10 6 cells/mL) were grown in minimum essential medium supplemented with 10% FBS in 35 mm cell culture dishes. At 90%
confluence, a wound was made using a sterile micropipette tip.
30,31
The floating cells were removed immediately after wounding, and the media were changed with fresh one containing different concentra- anti-mouse IgG conjugated to Alexa Fluor 568. The DNA was stained with Hoechst 33342 to visualize the DNA. Gamma tubulin staining was performed using rabbit monoclonal anti-gamma tubulin antibody at 1:1000 dilutions as described earlier. 27, 32, 33 Immunofluorescence images were acquired using the CoolSNAP digital camera and were processed by using ImageJ (NIH, USA).
| Molecular docking study
The interaction of zerumbone with tubulin dimer and other cell division proteins such as Eg5, Aurora A, Plk1, Kif2 and Nek2 was analysed through molecular docking. The 3D crystal coordinates of tubulin heter- Then, they were energy-minimized until the average RMSD of the non- 
| Purification of tubulin
Goat brain tubulin was isolated by two cycles of polymerization
and depolymerization in the presence of glutamate as described earlier. 34, 35 Bradford assay was used to estimate the tubulin concentration using bovine serum albumin as the standard. 36 The protein was stored in aliquots at −80°C until further use. All the experiments with tubulin were performed in PEM buffer (25 mmol/L PIPES, 1 mmol/L EGTA, 3 mmol/L MgCl 2 , pH 6.8).
| Spectral measurements
All the absorbance measurements were carried out in Systronics 
| Determination of Kd
where L f is the concentration of free zerumbone. 30, 39 The experiment was repeated three times.
| Sedimentation assay
The in vitro microtubule sedimentation assay was performed to detect the effect of zerumbone on the polymerization of tubulin.
Different concentrations of zerumbone were incubated with tubulin (12 μmol/L) in PEM buffer containing 0.8 mol/L glutamate and 1 mmol/L GTP at 37°C for 1 hour. The reaction mixture was then subjected to centrifugation at 50 000 × g for 1 hour. The supernatant and pellet were collected separately, and the protein concentration in the supernatant was measured using Bradford assay. 
| Light scattering assay
The effect of zerumbone on the assembly of microtubule was also analysed by monitoring the kinetics of tubulin polymerization.
Different concentrations of zerumbone were added to 12 μmol/L tubulin in the polymerization buffer containing 25 mmol/L PIPES, 1 mmol/L EGTA, 3 mmol/L MgCl2 and 0.8 mol/L glutamate. The assembly reaction was initiated by adding 1 mmol/L GTP and incubated at 37°C. 38 The polymerization of tubulin was monitored by light scattering at 550 nm for 15 minutes using JASCO FP-8300 spectrofluorometer (Tokyo, Japan) connected with circulating water bath maintained at 37°C.
| Binding site competition assay
Colchicine has a very weak fluorescence in aqueous buffers but exhibits a strong fluorescence after binding to tubulin. 40 This fluorescence property of colchicine is exploited in binding site competition assays to predict the binding site of unknown compounds. Tubulin
(1 μmol/L) was incubated with colchicine (10 μmol/L) for 1 hour at 37°C to form a stable tubulin-colchicine (T-C) complex which has several fold higher fluorescence than unbound colchicine. 40 
Different
concentrations of zerumbone were then added to the T-C complex and incubated for further 30 minutes at 37°C. The samples were excited at 360 nm, and the emission spectra were recorded. 30, 39 Alternatively, competition assay was also done using the fluores- 
| Determination of combination index
HeLa cells were incubated with zerumbone or vinblastine or pacli- where D m is the median dose, f a is the fraction affected, and f u is the fraction unaffected (f u = 1 − f a ). The median dose (D m ) was calculated as described earlier. 42 A CI < 1 indicates synergism, CI = 1
shows additivity, and CI > 1 specifies antagonism. HeLa cells grown on coverslips in 24-well tissue culture plate were treated with zerumbone in combination with paclitaxel or vinblastine and processed to visualize microtubules and DNA.
| RE SULTS
| Isolation and characterization
The methanolic extract of 1 kg of fresh Zingiber zerumbet extract yielded 1.8 g of crystalline zerumbone. The isolated product showed M+ ion at 219 when analysed by LC-MS ( Figure 1A ). 
| Selective toxicity of zerumbone on the proliferation of cancer cells
Zerumbone inhibited the proliferation of human cervical cancer cell 
| Zerumbone inhibited the migration of HeLa cells in a concentration-dependent manner
Wound healing assay was used to check the migration of HeLa cells upon treatment with different concentrations of zerumbone.
As shown in Figure 4A , to be 3%, 7% and 27%, respectively, and the MI, which is the ratio of the total number of the mitotic cells to the total cells, was found to be 15%, 20% and 34%, respectively. Under similar conditions, the MI of the control cells was 3.5% ( Figure 5D ).
| Probing the possible targets of zerumbone through computational docking analysis
Since zerumbone treatment produced cells with mitotic abnormalities, we investigated the interaction of the zerumbone with cell division proteins such as tubulin, Eg5, Aurora A, Plk1, (Table 1) and MM-GBSA scoring, it is possible to speculate that Eg5 and Aurora kinase A could also be the potential target for zerumbone in addition to tubulin.
| Binding of zerumbone to tubulin
Results from the cell culture studies and docking analysis indicated that tubulin could be one of the primary targets for Zerumbone.
Hence, binding of zerumbone on tubulin was analysed using 
| Zerumbone inhibited the polymerization of tubulin in vitro
The effect of zerumbone on tubulin assembly was analysed by using the sedimentation assay and the light scattering The data shown are mean ± SD of three independent experiments (*P < 0.001; ‡ P < 0.01; †P < 0.05)
of zerumbone-vinblastine and zerumbone-paclitaxel is strongly synergistic in inhibiting the proliferation of HeLa cells.
The effect of the combination of zerumbone with vinblastine and paclitaxel on mitotic cells was analysed by calculating the MI.
Zerumbone synergistically increased the MI in combination with vinblastine and paclitaxel. As shown in Figure 11A , vinblastine when used alone induced a mitotic block of 9.4%; however, when combined with zerumbone 5, 10 and 12 µmol/L, the mitotic block was increased to 20%, 25% and 31%, respectively. Similarly, vinblastine 1.2 nmol/L when used alone induced a mitotic block of 19%, and when combined with zerumbone 5, 10 and 12 µmol/L, the mitotic block was found to be increased 28%, 38% and 46%, respectively. Zerumbone induced a significant hike in the mitotic cells when combined with paclitaxel, similar to its synergistic activity with vinblastine. When 5 nmol/L paclitaxel was combined with 10 and 12 µmol/L zerumbone, the MI was found to be 32%
and 37%, respectively ( Figure 11B ), and when 10 nmol/L paclitaxel was combined with 10 and 12 µmol/L zerumbone, the MI was increased to 54% and 60%, respectively, while paclitaxel alone at 5
and 10 nmol/L induced 15% and 31% mitotic block ( Figure 11B ). In addition to the enhanced mitotic arrest, the combined addition of two drugs induced drastic mitotic abnormalities in the organization of the mitotic spindle and alignment of chromosomes ( Figures   11C,D) .
| D ISCUSS I ON
Several secondary metabolites from plants have successful application as chemotherapeutic agents either in their unmodified The significance of plants as a major source of anti-cancer agents can be understood from the fact that most of the presently used chemotherapeutic agents are derived from natural sources in one way or the other. 51 In this study, we have found that the potential mechanism behind the anti-cancer activity of zerumbone is through its inhibitory activity on tubulin polymerization and mitotic arrest.
Results from LC-MS and NMR were in conformity with the molecular weight (218.34) and the structure of the compound. The data were in agreement with the earlier published reports. 25 Our Glide docking score, ΔG binding, number of hydrogen bonds and interacting residues are shown.
be used as a relatively less toxic, safe and effective chemotherapeutic agent. Curcumin, the dihydroxy polyphenol from Curcuma longa, was also reported to induce selective toxicity in cancer cells due to preferential uptake by the cancer cells compared to normal cells. 29 AO staining was used to analyse whether the cytotoxic effect of zerumbone was due to necrotic cell death or apoptosis. Microtubules play a very important role in cell migration, 54 and most of the potent tubulin-targeted drugs inhibit the migration of the cell at concentrations lower than their IC 50 .
55,56
Since zerumbone showed excellent mitotic block and inhibited the migration of cancer cells, we analysed the effect of zerumbone on interphase and mitotic microtubules using immunofluorescence microscopy. In our study, we observed that zerumbone at IC 50 
58-60
The nearly equal affinity of zerumbone towards Eg5 and Aurora A obtained by docking analysis indicated that it might target both the proteins or any one which can be confirmed only through in vitro analysis. It is important to note that zerumbone at its IC 50 other antimitotic drugs, which at higher concentration will activate the apoptotic pathways much earlier in the cell cycle. 32, 61, 62 Results from the docking studies and the cell culture studies in which zerumbone induced a strong mitotic block and depolymerization of interphase microtubules motivated us to study its effect on purified tubulin isolated from goat brains using fluorescence spectroscopy. Tubulin heterodimer contains eight tryptophan residues, and interaction of small molecules will disturb the conformation of tubulin, leading to change in the intrinsic fluorescence contributed by the tryptophan residues. 38 Zerumbone binding to tubulin with a Kd of 4 μmol/L indicates that it has a high affinity for tubulin.
The effects of microtubule targeted drugs on the polymerization ing the microtubule dynamics. 34, 65 It is reasonable to assume that the synergistic activity of zerumbone with vinblastine and taxol could be due to the strong suppression of microtubule dynamics.
The mechanism of action of zerumbone was similar to that of the other clinically used chemotherapeutic drugs such as vinblastine and paclitaxel, which bind to tubulin and induce mitotic block. In addition to tubulin, zerumbone might have another target involved in centrosome separation that gets inhibited only at higher concentrations.
Our finding that internalization of zerumbone is higher in cancer cells leading to it preferential killing and that it is highly effective in preventing the migration of cancer cells will be more valuable in 
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